- Home
- XRTX vs BGMS Comparison
XRTX vs BGMS Comparison
Compare XRTX & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XRTX | BGMS |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Canada | Malaysia |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XRTX | BGMS |
|---|---|---|
| Price | $0.41 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 208.5K | 175.9K |
| Earning Date | 03-20-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.46 |
| 52 Week Low | $0.38 | $0.74 |
| 52 Week High | $1.41 | $100.75 |
Technical Indicators
Market Signals| Indicator | XRTX | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 37.36 |
| Support Level | $0.38 | $0.98 |
| Resistance Level | $0.45 | $1.06 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 26.85 | 38.43 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.